Two proteins, human plasma BuChE, and a recombinant human BuChE are both in advanced development as potential prophylacitcs for protecting against chemical warfare agents. These proteins react rapidly and stoiciometrically to effectively scavenge the poisons in the blood stream but they require relatively large amounts of protein to provide protection. The challenge of identifying a protein based drug that would require less material while providing improved protection with the advantage of enhanced user acceptance cannot be ignored. Recent efforts the laboratories alinged with the Center have identified several human enzymes, paraoxonase (PON) and a mutant of butyrylcholinesterase that can catalyze the hydrolysis of all nerve agents. As such these are excellent candidate for prophylactic administration to provide protection for first responders to a terrorist attack or military forces in a civilian peacekeeping setting subject to an asymmetric threat. If it were administered intravenously it could also serve as a rapid-onset therapeutic antidote to a segment of the civilian popuation exposed to nerve agents. Preliminary studies have shown that these objectives are both feasible and obtainable. The cost/benefit ratio of such a drug is such that it is an excellent candidate for success and has the potential to be the first in a series of a novel class of drugs. The center will coordinate the overall effort directed toward the enhancement of the the native catalytic activity of these human enzymes to create a viable candidate for transition to advancement to clinical trials within a five year period. This will address a critical gap in the national goal of protecting the civilian population against a terrorist-initiated chemical weapons attack.
Current medical protection against chemical nerve agent exposure by terrorists is limited to post exposure treatment. We will identify and develop for clinical testing a human protein capable of providing rapid and long lasting prophylactic protection against exposure to chemical warfare nerve agents. Such a drug will address the critical national goal of providing improved protection to the general population against a terrorist-initiated chemical weapons attack.
|Dwyer, Mary; Javor, Sacha; Ryan, Daniel A et al. (2014) Novel human butyrylcholinesterase variants: toward organophosphonate detoxication. Biochemistry 53:4476-87|
|Rockah-Shmuel, Liat; Tawfik, Dan S; Goldsmith, Moshe (2014) Generating targeted libraries by the combinatorial incorporation of synthetic oligonucleotides during gene shuffling (ISOR). Methods Mol Biol 1179:129-37|
|Schneider, Jeannine D; Castilho, Alexandra; Neumann, Laura et al. (2014) Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. Biotechnol J 9:501-10|
|Jiang, Wei; Cashman, John R; Nachon, Florian et al. (2013) Mass spectrometry method to identify aging pathways of Sp- and Rp-tabun adducts on human butyrylcholinesterase based on the acid labile P-N bond. Toxicol Sci 132:390-8|
|Ben-David, Moshe; Wieczorek, Grzegorz; Elias, Mikael et al. (2013) Catalytic metal ion rearrangements underline promiscuity and evolvability of a metalloenzyme. J Mol Biol 425:1028-38|
|Goldsmith, Moshe; Tawfik, Dan S (2013) Enzyme engineering by targeted libraries. Methods Enzymol 523:257-83|
|Luechapanichkul, Rinrada; Chen, Xianwen; Taha, Hashem A et al. (2013) Specificity profiling of dual specificity phosphatase vaccinia VH1-related (VHR) reveals two distinct substrate binding modes. J Biol Chem 288:6498-510|
|Goldsmith, Moshe; Ashani, Yacov; Simo, Yair et al. (2012) Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. Chem Biol 19:456-66|
|Ben-David, Moshe; Elias, Mikael; Filippi, Jean-Jacques et al. (2012) Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol 418:181-96|
|Styslinger, Thomas J; Zhang, Ning; Bhatt, Veer S et al. (2012) Site-selective glycosylation of hemoglobin with variable molecular weight oligosaccharides: potential alternative to PEGylation. J Am Chem Soc 134:7507-15|
Showing the most recent 10 out of 33 publications